Isomorphic Labs, an AI-first drug design and development company, today announced it has raised $600 Million in its first external funding round. The financing round is led by Thrive Capital, with ...

In March 2025, Isomorphic Labs raised $600m via a financing round led by Thrive Capital, which has been used to continue developing the AI drug-design engine and advance the pipeline into clinical ...

Isomorphic Labs has raised a whopping $600 million to refine its artificial intelligence-powered drug discovery engine, advance its pipeline, and expand its headcount in its first external funding ...

Isomorphic Labs, an Alphabet-backed AI biotech firm, raised $600M to boost its AI drug design engine, expand clinical programs, and accelerate disease research. Close. Latest News; ...

Isomorphic announced on Monday that it had raised $600 million, led by Thrive Capital, the venture capital firm that has bet big on A.I. companies including OpenAI.

Isomorphic Labs. BioPharma, Startups An AI Biotech Hauls In $600M, Plus More Funding Highlights to Close 1Q 2025 Isomorphic Labs’ financing led the way for first quarter 2025 financings , but it ...

Isomorphic Labs, Google’s artificial intelligence drug business, raised $600 million in its first external funding round, the company said on Monday. Thrive Capital, a venture capital firm, led ...

Isomorphic Labs will utilise the funding to further power its AI drug design engine through frontier AI research and development and to scale and progress its drug candidate pipeline.